Header Logo
Last Name

You can now add alternative names! Click here to add other names that you've published under.


Search Results to Carolina Schinke

This is a "connection" page, showing the details of why an item matched the keywords from your search.


One or more keywords matched the following properties of Schinke, Carolina

overview Dr. Carolina Schinke is an Associate Professor of Medicine at the Myeloma Institute for Research and Therapy at UAMS and joined the department in 2014. She completed her fellowship in Hematology/Oncology in 2013 at Montefiore Medical Center in New York and performed a research fellowship in molecular and translational science at Einstein, New York in 2014 . She earned her medical degree at the University of Halle in Germany and completed her residency at the Jacobi Medical Center in New York in 2010. Dr. Schinke has several publications and scientific poster presentations/abstracts and is a member of the American Society of Hematology, American Society of Oncology and International Myeloma Society. Her clinical interests are plasma cell dyscrasias, including MGUS, smoldering multiple myeloma, plasma cell leukemia as well as amyloid disease and Waldenstroms.

One or more keywords matched the following items that are connected to Schinke, Carolina

Item TypeName
Academic Article Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.
Academic Article Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.
Concept Cell Communication
Concept Cell Cycle
Concept Clone Cells
Concept Cell Transformation, Neoplastic
Concept Cell Differentiation
Concept Hematopoietic Stem Cells
Concept Hematopoietic Stem Cell Transplantation
Concept Cell Survival
Concept Myeloid Progenitor Cells
Concept Neoplasms, Plasma Cell
Concept Cell Proliferation
Concept Cell Lineage
Concept Stem Cell Transplantation
Concept Plasma Cells
Concept Lymphoma, B-Cell
Concept Cell Line, Tumor
Concept Leukemia, Plasma Cell
Concept Tumor Cells, Cultured
Concept Receptors, Antigen, T-Cell
Concept Megakaryocyte Progenitor Cells
Concept Neoplastic Stem Cells
Concept Lymphoma, Large B-Cell, Diffuse
Concept B-Cell Maturation Antigen
Concept Primary Cell Culture
Concept Precursor Cell Lymphoblastic Leukemia-Lymphoma
Concept Cell Cycle Checkpoints
Academic Article Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.
Academic Article Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
Academic Article IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
Academic Article Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Academic Article Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
Academic Article Gastrointestinal histoplasmosis in a patient after autologous stem cell transplant for multiple myeloma.
Academic Article Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant.
Academic Article The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.
Academic Article Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.
Academic Article The genomic landscape of plasma cells in systemic light chain amyloidosis.
Academic Article Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.
Academic Article Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias.
Academic Article The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia.
Academic Article Long-term outcomes after autologous stem cell transplantation for multiple myeloma.
Academic Article Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
Academic Article Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.
Academic Article The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
Academic Article Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
Academic Article The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
Academic Article PHF19 inhibition as a therapeutic target in multiple myeloma.
Academic Article High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse.
Academic Article Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
Academic Article Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma.
Academic Article The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma.
Academic Article Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.
Academic Article Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
Academic Article Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.
Academic Article First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenstr?m's Macroglobulinemia: A systematic review and meta-analysis.
Academic Article Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
Academic Article CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
Academic Article Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.
Academic Article Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
Academic Article Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.
Academic Article Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
Academic Article A gene signature can predict risk of MGUS progressing to multiple myeloma.
Academic Article Growth and dormancy control of myeloma cells by mesenchymal stem cells.
Academic Article The Immune Microenvironment in Multiple Myeloma Progression at a Single-cell Level.
Academic Article Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level.
Academic Article EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression.
Academic Article The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Academic Article Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States.
Academic Article BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
Academic Article High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma.
Grant MAGNETISMM-4 A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma
Grant MAGNETISMM-4 A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma
Academic Article Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Academic Article Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
Academic Article Synchronous plasma cell neoplasm and B lymphoblastic leukemia/lymphoma at initial presentation: first report of an unusual association with a good outcome.
Academic Article Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma.
Academic Article Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency.
Academic Article Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study.
Academic Article Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Academic Article The impressive efficacy of anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma.
Academic Article A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.

Search Criteria
  • Cells